147 related articles for article (PubMed ID: 34814708)
1. Selective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategy.
Mallareddy JR; Singh S; Boghean L; Natarajan A
Future Med Chem; 2022 Jan; 14(3):131-134. PubMed ID: 34814708
[No Abstract] [Full Text] [Related]
2. Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.
Sonawane YA; Taylor MA; Napoleon JV; Rana S; Contreras JI; Natarajan A
J Med Chem; 2016 Oct; 59(19):8667-8684. PubMed ID: 27171036
[TBL] [Abstract][Full Text] [Related]
3. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
King HM; Rana S; Kubica SP; Mallareddy JR; Kizhake S; Ezell EL; Zahid M; Naldrett MJ; Alvarez S; Law HC; Woods NT; Natarajan A
Bioorg Med Chem Lett; 2021 Jul; 43():128061. PubMed ID: 33895280
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.
Bian J; Ren J; Li Y; Wang J; Xu X; Feng Y; Tang H; Wang Y; Li Z
Bioorg Chem; 2018 Dec; 81():373-381. PubMed ID: 30196207
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
[TBL] [Abstract][Full Text] [Related]
6. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
[TBL] [Abstract][Full Text] [Related]
7. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Wu T; Qin Z; Tian Y; Wang J; Xu C; Li Z; Bian J
J Med Chem; 2020 Nov; 63(22):13228-13257. PubMed ID: 32866383
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.
Olson CM; Jiang B; Erb MA; Liang Y; Doctor ZM; Zhang Z; Zhang T; Kwiatkowski N; Boukhali M; Green JL; Haas W; Nomanbhoy T; Fischer ES; Young RA; Bradner JE; Winter GE; Gray NS
Nat Chem Biol; 2018 Feb; 14(2):163-170. PubMed ID: 29251720
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of Wee1 kinase degraders.
Zhu S; Liu J; Xiao D; Wang P; Ma J; Hu X; Fu J; Zhou Y; Li J; Lu W
Eur J Med Chem; 2022 Dec; 243():114786. PubMed ID: 36170799
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
Jing L; Tang Y; Xiao Z
Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
Alsfouk A
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
Barlaam B; De Savi C; Dishington A; Drew L; Ferguson AD; Ferguson D; Gu C; Hande S; Hassall L; Hawkins J; Hird AW; Holmes J; Lamb ML; Lister AS; McGuire TM; Moore JE; O'Connell N; Patel A; Pike KG; Sarkar U; Shao W; Stead D; Varnes JG; Vasbinder MM; Wang L; Wu L; Xue L; Yang B; Yao T
J Med Chem; 2021 Oct; 64(20):15189-15213. PubMed ID: 34647738
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9.
Itkonen HM; Poulose N; Steele RE; Martin SES; Levine ZG; Duveau DY; Carelli R; Singh R; Urbanucci A; Loda M; Thomas CJ; Mills IG; Walker S
Mol Cancer Res; 2020 Oct; 18(10):1512-1521. PubMed ID: 32611550
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
Wei D; Wang H; Zeng Q; Wang W; Hao B; Feng X; Wang P; Song N; Kan W; Huang G; Zhou X; Tan M; Zhou Y; Huang R; Li J; Chen XH
J Med Chem; 2021 Oct; 64(19):14822-14847. PubMed ID: 34538051
[TBL] [Abstract][Full Text] [Related]
15. A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL.
Tong B; Spradlin JN; Novaes LFT; Zhang E; Hu X; Moeller M; Brittain SM; McGregor LM; McKenna JM; Tallarico JA; Schirle M; Maimone TJ; Nomura DK
ACS Chem Biol; 2020 Jul; 15(7):1788-1794. PubMed ID: 32568522
[TBL] [Abstract][Full Text] [Related]
16. Effects of Cyclin Dependent Kinase 9 inhibition on zebrafish larvae.
Matrone G; Mullins JJ; Tucker CS; Denvir MA
Cell Cycle; 2016 Nov; 15(22):3060-3069. PubMed ID: 27715402
[TBL] [Abstract][Full Text] [Related]
17. Development of selective mono or dual PROTAC degrader probe of CDK isoforms.
Zhou F; Chen L; Cao C; Yu J; Luo X; Zhou P; Zhao L; Du W; Cheng J; Xie Y; Chen Y
Eur J Med Chem; 2020 Feb; 187():111952. PubMed ID: 31846828
[TBL] [Abstract][Full Text] [Related]
18. Halogen bonds form the basis for selective P-TEFb inhibition by DRB.
Baumli S; Endicott JA; Johnson LN
Chem Biol; 2010 Sep; 17(9):931-6. PubMed ID: 20851342
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase.
Degorce SL; Tavana O; Banks E; Crafter C; Gingipalli L; Kouvchinov D; Mao Y; Pachl F; Solanki A; Valge-Archer V; Yang B; Edmondson SD
J Med Chem; 2020 Sep; 63(18):10460-10473. PubMed ID: 32803978
[TBL] [Abstract][Full Text] [Related]
20. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]